A 12 Month, Single-center, Non-randomized, Open-label Study of Outcomes of Intermediate Risk Maryland Aggregate Pathology Index (MAPI) Scores in de Novo Renal Transplant Recipients.
Phase of Trial: Phase II
Latest Information Update: 21 Jun 2018
At a glance
- Drugs Belatacept (Primary)
- Indications Renal transplant rejection
- Focus Therapeutic Use
- 13 Jun 2018 Status changed from active, no longer recruiting to completed.
- 16 Aug 2017 Planned primary completion date changed from 1 Jan 2017 to 1 Jan 2018.
- 16 Aug 2017 Status changed from recruiting to active, no longer recruiting.